Lo Seong Loong, Wang Shu
Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, #04-01, 138669 Singapore, Singapore.
Macromol Rapid Commun. 2010 Jul 1;31(13):1134-41. doi: 10.1002/marc.200900934. Epub 2010 May 17.
Successful molecular therapy using protein-based therapeutic agents for intracellular targets depends on the development of efficient and safe protein delivery systems that are able to overcome the problem of poor permeability of cell membrane to proteins. Here, we summarize recent studies elucidating how one particular class of peptide-based carriers, amphipathic peptide, has been designed and utilized for intracellular protein delivery in a simple yet effective manner. The unique feature of these delivery systems lies in the noncovalent binding of amphipathic peptides to protein cargos, mainly through hydrophobic interactions. At least five different types of amphipathic peptides have been developed and demonstrated to be able to deliver various biologically active proteins into a variety of cell types without the use of chemical conjugation. In view of their efficiency and presumably low toxicity, we anticipate that amphipathic peptides will continue to be developed as powerful carriers for intracellular delivery of protein therapeutics.
使用基于蛋白质的治疗剂针对细胞内靶点进行成功的分子治疗,依赖于高效且安全的蛋白质递送系统的开发,该系统需能够克服细胞膜对蛋白质通透性差这一问题。在此,我们总结了近期的研究,这些研究阐明了一类特殊的基于肽的载体——两亲性肽,是如何以一种简单而有效的方式被设计并用于细胞内蛋白质递送的。这些递送系统的独特之处在于两亲性肽与蛋白质货物的非共价结合,主要通过疏水相互作用实现。至少已开发出五种不同类型的两亲性肽,并证明它们能够在不使用化学偶联的情况下,将各种生物活性蛋白质递送至多种细胞类型中。鉴于其效率以及推测的低毒性,我们预计两亲性肽将继续被开发成为用于细胞内递送蛋白质治疗剂的强大载体。